The European Commission could issue fines to the world’s largest generic drug makers as early as next month, according to unnamed sources.
Leading generic firms Teva Pharmaceutical and Les Laboratoires Servier, along with other generic competitors, are under the Commission’s crackdown for alleged anticompetitive agreements made with brand name rivals, deals that are known as pay-for-delay schemes in which generic firms accept payment from brand name firms to delay the release of their cheaper, competing drugs.
Unnamed sources said Thursday that as many as six companies, including Teva and Servier, could be issued fines by the end of next month, before the Commission goes on vacation.
EU authorities first launched an inquiry into the pharmaceutical industry in 2008, leading to multiple antitrust investigations.
Full content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Canadian Breadmakers Settle Price-Fixing Lawsuit
Jul 25, 2024 by
CPI
EssilorLuxottica Open to Meta as Shareholder, Says CEO Francesco Milleri
Jul 25, 2024 by
CPI
California Supreme Court Upholds Proposition 22, Securing Independent Contractor Status for Uber and Lyft Drivers
Jul 25, 2024 by
CPI
Paramount Global Investor Sues to Block Skydance Media Merger
Jul 25, 2024 by
CPI
Software Vendors Win Class Action Status in Antitrust Case Against CDK Global
Jul 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Trade & Antitrust
Jul 26, 2024 by
CPI
What is Wrong with the WTO Discipline on Subsidies?
Jul 26, 2024 by
CPI
The Abiding Tension Between Trade Remedy Law and Antitrust
Jul 26, 2024 by
CPI
Trade and Antitrust: An End to Isolationism
Jul 26, 2024 by
CPI
International Trade Law and Domestic Regulation of Generative Artificial Intelligence: Divergent Approaches?
Jul 26, 2024 by
CPI